Cargando…

Advances in targeted alpha therapy for prostate cancer

Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. In this review, we discuss the history, progress, and future potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Vincentis, G, Gerritsen, W, Gschwend, J E, Hacker, M, Lewington, V, O’Sullivan, J M, Oya, M, Pacilio, M, Parker, C, Shore, N, Sartor, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927314/ https://www.ncbi.nlm.nih.gov/pubmed/31418764 http://dx.doi.org/10.1093/annonc/mdz270

Ejemplares similares

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
por: Sartor, O., et al.
Publicado: (2017)

Radium and other alpha emitters in prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2018)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
por: O’Sullivan, Joe M., et al.
Publicado: (2022)

Targeted Alpha-Particle Therapy: A Review of Current Trials
por: Jang, Albert, et al.
Publicado: (2023)

Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2016)

Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy
por: O'Neill, A.G.M., et al.
Publicado: (2019)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Differential responses to (223)Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
por: Guerra Liberal, Francisco D. C., et al.
Publicado: (2022)

Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
por: Brown, Malcolm, et al.
Publicado: (2019)

Advances in Faba Bean Genetics and Genomics
por: O'Sullivan, Donal M., et al.
Publicado: (2016)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
por: Beer, Tomasz M., et al.
Publicado: (2022)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

Recent advances in the transesterification of β-keto esters
por: Hennessy, M. C., et al.
Publicado: (2021)

Cognitive Functional Therapy: An Integrated Behavioral Approach for the Targeted Management of Disabling Low Back Pain
por: O’Sullivan, Peter B, et al.
Publicado: (2018)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy
por: Ceder, Jens, et al.
Publicado: (2017)

Alpha Satellite DNA in Targeted Drug Therapy for Prostate Cancer
por: Feliciello, Isidoro, et al.
Publicado: (2023)

A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy
por: Haseen, Farhana, et al.
Publicado: (2010)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
por: Gillessen, S., et al.
Publicado: (2015)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Erratum to “Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy” [Tech. Innov. Patient Support Radiat. Oncol. 9 (2019) 35–40]
por: O'Neill, A.G.M., et al.
Publicado: (2019)

Treating the patient and not just the cancer: therapeutic burden in prostate cancer
por: Spratt, Daniel E., et al.
Publicado: (2021)

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
por: Beer, Tomasz M, et al.
Publicado: (2015)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer
por: Spratt, Daniel E., et al.
Publicado: (2021)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
por: Pacilio, Massimiliano, et al.
Publicado: (2022)

Microdosimetry for Targeted Alpha Therapy of Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2012)

DNA Damage Repair Defects and Targeted Radionuclide Therapies for Prostate Cancer: Does Mutation Really Matter? A Systematic Review
por: Filippi, Luca, et al.
Publicado: (2022)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Alpha-synuclein alters the faecal viromes of rats in a gut-initiated model of Parkinson’s disease
por: Stockdale, Stephen R., et al.
Publicado: (2021)

Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study
por: Cardwell, Chris R., et al.
Publicado: (2021)

New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer
por: Godbole, Abhijit M., et al.
Publicado: (2011)

[(11)C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy
por: Schwarzenböck, Sarah M., et al.
Publicado: (2016)

The Importance of Alpha-Actinin Proteins in Platelet Formation and Function, and Their Causative Role in Congenital Macrothrombocytopenia
por: O’Sullivan, Leanne R., et al.
Publicado: (2021)

Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy
por: Hagemann, Urs B., et al.
Publicado: (2020)

What is the Role of the Bystander Response in Radionuclide Therapies?
por: Brady, Darren, et al.
Publicado: (2013)

Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?
por: O'Sullivan, Kim M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pipc7vatlcjfsi9ndol1g8gevk